Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. Methods: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. Results: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). Conclusion: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.

Pia Sormani, M., Schiavetti, I., Landi, D., Carmisciano, L., De Rossi, N., Cordioli, C., et al. (2022). SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. MULTIPLE SCLEROSIS, 28(7), 1034-1040 [10.1177/13524585211035318].

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Mario Alberto Battaglia;Daiana Bezzini
Membro del Collaboration Group
;
Nicola De Stefano
Membro del Collaboration Group
;
Monica Ulivelli
Membro del Collaboration Group
2022

Abstract

Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. Methods: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. Results: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). Conclusion: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
Pia Sormani, M., Schiavetti, I., Landi, D., Carmisciano, L., De Rossi, N., Cordioli, C., et al. (2022). SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. MULTIPLE SCLEROSIS, 28(7), 1034-1040 [10.1177/13524585211035318].
File in questo prodotto:
File Dimensione Formato  
13524585211035318.pdf

non disponibili

Descrizione: Free full text sul sito dell'editore: https://journals.sagepub.com/doi/10.1177/13524585211035318
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 494.21 kB
Formato Adobe PDF
494.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/1167747